JAMA Network
About The Study: In this study of 6.3 million older U.S. adults, the mRNA-1273 (Moderna) vaccine was associated with a slightly lower risk of several adverse events compared with BNT162b2 (Pfizer-BioNTech), possibly due to greater protection against COVID-19. Future research should seek to formally disentangle differences in vaccine safety and effectiveness and consider the role of frailty in assessments of COVID-19 vaccine performance.
Authors: Daniel A. Harris, Ph.D., of the Brown University School of Public Health in Providence, Rhode Island, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2023.26852)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
